ILE Isolagen

Isolagen to Host Conference Call to Discuss Positive Phase II Dental Study Results EXTON, Pa., July 11 /PRNewswire-FirstCall/ -- Isolagen, Inc. (AMEX:ILE) will host a conference call on July 13, 2005 beginning at 4:30 P.M. EDT to discuss the recently reported positive results of its Phase II dental study. Results from the study, conducted by Dr. Michael McGuire to determine the safety and efficacy of the Isolagen Process for the treatment of interdental papillary insufficiency commonly referred to as "black triangles," demonstrated that the Isolagen Process was statistically superior to placebo at 4 months after treatment. Isolagen invites all those interested in hearing management's discussion of the Phase II dental study results to join the call by dialing 1 (800) 901-5231. International participants may access the call by dialing 1 (617) 786-2961. A replay will be available for one week following the call by dialing 1 (888) 286-8010 for domestic participants or 1 (617) 801-6888 for international participants and entering access code 25341604 when prompted. Participants may also access a live web-cast of the conference call through the investor relations section of Isolagen's web site, http://www.isolagen.com/ . About Isolagen, Inc. Isolagen specializes in the development and commercialization of autologous cellular therapies for soft and hard tissue regeneration. The company's product candidates are based on its proprietary Isolagen Process. Based on the accumulated experience of the company through its retrospective study, clinical trials and treatment of patients in the United Kingdom, the company believes that the Isolagen Process utilizes the patient's own cells to create safe and effective therapies to treat the underlying cause of the patient's condition. Autologous cellular therapy is the process whereby a patient's own cells are extracted, allowed to multiply and then injected into the patient. Isolagen's product candidates are designed to be minimally invasive and non-surgical. Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. Information contained in forward-looking statements is based on current expectations and is subject to change, and actual results may differ materially from the forward-looking statements. Isolagen, Inc. does not undertake to update any such forward-looking statements or to publicly announce developments or events relating to the matters described herein. For additional information, please visit: http://www.isolagen.com/ . DATASOURCE: Isolagen, Inc. CONTACT: Martin Schmieg, Chief Financial Officer of Isolagen, Inc., +1-484-875-3099; or investor relations, Kate McNeil, or John Nesbett, +1-212-825-3210, for Isolagen, Inc. Web site: http://www.isolagen.com/

Copyright